Randomized, Open Label Safety Trial of Dapivirine Vaginal Ring and Oral TRUVADA® Use in Pregnancy
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the maternal and infant safety of the dapivirine
(DPV) vaginal ring (VR) and daily oral Truvada in HIV-uninfected pregnant women and their
infants.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Dapivirine Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Tenofovir